Over the past year, important contributions have been made in sickle cell research. This progress are critical steps towards finding new treatments and a universal cure for sickle cell conditions.

Novartis Investigational Therapy Crizanlizumab (SEG101) Receives FDA Breakthrough Therapy Designation for the Prevention of Vaso-occlusive Crises in Sickle Cell Disease.

Read more

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease.

Read more

GBT Announces the FDA Agrees to Submit a New Drug Application for the Approval of Voxelotor.

Read more

FDA Approves Hydroxyurea Tablets for Pediatric Sickle Cell Anemia

Read more

Imara Doses First Patient in Phase 2a Clinical Trial of IMR-687 for Sickle Cell Disease.

Read more

Emmaus Life Sciences Announces Availability of Endari™ (L-glutamine oral powder) for Sickle Cell Disease in the United States.

Read more

U.S. Food and Drug Administration granted regular approval to hydroxyurea to reduce the frequency of painful crises and the need for blood transfusions in pediatric patients from 2 years of age and older with sickle cell anemia with recurrent moderate to severe painful crises.

Read more